Upon approval of medicines for Japan, Shionogi will pay a one-time fee and share costs with Shire, which has several ADHD drugs on the market.

Intent on tapping one of the world’s fastest-growing markets for ADHD treatments, Shire and Japan’s Shionogi & Co. agreed to co-develop and co-commercialize some of Shire’s medicines for the psychiatric behavioral disorder. Upon approval of medicines for Japan, Shionogi will pay a one-time fee and share costs with Shire.

Shire’s drugs for ADHD include Adderall XR, Intuniv, Vyvanse. All three recorded double-digit year-over-year sales gains during the third quarter, with the first two increasing by 50%, and Vyvanse, by 32%. Shionogi develops medicines for the central nervous system, among other therapeutic areas.

The agreement comes nearly three years after Shire opened a representative office in Japan, with the goal of stepping up commercialization of its pipeline products in Japan, the world’s second largest biopharmaceutical market.

Previous articleFDA Clears EUSA’s Asparaginase Therapy Erwinaze for Acute Lymphoblastic Leukemia
Next articleBC Cancer Agency Buys RainDance’s ThunderStorm High-Throughput Sequencing System